Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) has announced that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Propofol Injectable Emulsion USP in single-dose…
QuantHealth, an AI-driven clinical trial design firm, has successfully simulated over 100 trials, achieving 85% accuracy and notable returns on investment for pharmaceutical partners. By utilizing its proprietary technology and…
Relief Mental Health, a top provider of transcranial magnetic stimulation (TMS), psychedelic therapy (including SPRAVATO® and IV ketamine), psychiatry, and talk therapy, has introduced TMS for smoking cessation at its…
AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted by the FDA for Priority Review. This application, based on the positive ADRIATIC Phase III trial results in…
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has announced that the European Medicines Agency (EMA) has validated their Marketing Authorization Application (MAA) for sebetralstat, an investigational oral plasma kallikrein inhibitor intended for…
Syros Pharmaceuticals (NASDAQ: SYRS) has announced it will halt enrollment in the SELECT-AML-1 Phase 2 trial, which is assessing the triplet combination of tamibarotene, venetoclax, and azacitidine versus the doublet…
Alpha Cognition Inc. (OTCQB: ACOG) (CSE: ACOG) has announced its financial results for the second quarter and six months ending June 30, 2024, along with a corporate update. CEO Michael…
Prothena Corporation plc (NASDAQ:PRTA), a leader in protein dysregulation-based therapies, reported its financial results for Q2 and the first half of 2024, alongside key business updates. Second Quarter and 2024…
Verastem Oncology, a biopharmaceutical firm dedicated to developing new cancer treatments, has provided an update on its business activities and financial performance for the second quarter ended June 30, 2024.…
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company specializing in novel small molecule therapies from its boron chemistry platform, today announced topline results from the Phase 2 portion of the…
Concentric Analgesics, Inc., a clinical-stage biopharmaceutical firm specializing in innovative non-opioid pain treatments, has unveiled new positive clinical data for vocacapsaicin, its leading product candidate for managing postsurgical pain. The…
Alzamend Neuro, Inc. (Nasdaq: ALZN), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder, has announced a partnership with…